Hyperliquid Strategies completes business combination; trades as PURR on Nasdaq Dec 3

Hyperliquid Strategies Inc

Closed acquisition of Sonnet BioTherapeutics and Rorschach I LLC; combined entity has ~127M shares outstanding.
New board of eight directors including Bob Diamond, Eric Rosengren, Thomas King; David Schamis remains CEO.
Issued to advisor warrants for up to 27.4M shares at exercise prices $9.375, $12.50, and $18.75.
Stock begins trading on Nasdaq Capital Market under ticker PURR on December 3, 2025.

item 2.01 item 1.01 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 5.05 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-025886
form_type: 8-K
ticker: PURR
cik: 0002078856
company_name: Hyperliquid Strategies Inc
filed_at: 2025-12-03T23:59:59+00:00
discovered_at: 2026-05-14T18:02:41.556178+00:00
generated_at: 2026-05-16T15:32:52.057751+00:00
sec_items: ["2.01", "1.01", "3.02", "3.03", "5.03", "5.01", "5.02", "5.05", "7.01", "8.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-025886
json_url: https://secwatch.observer/filing/0001493152-25-025886.json
markdown_url: https://secwatch.observer/filing/0001493152-25-025886.md
text_url: https://secwatch.observer/filing/0001493152-25-025886.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2078856/000149315225025886/0001493152-25-025886-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2078856/000149315225025886/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-025886

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.